Therapeutic decisions under uncertainty for spinal muscular atrophy: The DECISIONS-SMA study protocol

The therapeutic landscape for spinal muscular atrophy has changed in the last few years, encompassing respiratory/motor function and life expectancy benefits. However, physicians still have the challenge of tailoring individuals' treatment to therapeutic goals, disease progression, patient/care...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 17; no. 2; p. e0264006
Main Authors: Saposnik, Gustavo, Díaz-Abós, Paola, Sánchez-Menéndez, Victoria, Álvarez, Carmen, Terzaghi, María, Maurino, Jorge, Brañas-Pampillón, María, Málaga, Ignacio
Format: Journal Article
Language:English
Published: United States Public Library of Science 15-02-2022
Public Library of Science (PLoS)
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The therapeutic landscape for spinal muscular atrophy has changed in the last few years, encompassing respiratory/motor function and life expectancy benefits. However, physicians still have the challenge of tailoring individuals' treatment to therapeutic goals, disease progression, patient/caregiver's preferences, and personal experience to achieve an optimal risk/benefit balance. This study aims to provide insight into the preferred treatment choices of pediatric neurologists managing spinal muscular atrophy in their daily practice and to recognize behavioral factors that may influence decision-making. This is a noninterventional, cross-sectional pilot study involving 50 pediatric neurologists managing spinal muscular atrophy in Spain. We designed an online platform that contains 13 simulated case scenarios of common presentations of patients with spinal muscular atrophy. The primary study outcome will be treatment preferences according to the percentages of participants who select treatment initiation when recommended, switch therapies when there is evidence of disease progression, and select treatment discontinuation when disease progression puts patients outside treatment recommendation (11 case scenarios). Secondary outcomes include therapeutic inertia prevalence (11 case scenarios), herding phenomenon prevalence (2 case scenarios), care-related regret prevalence (specific questions) and intensity (10-item Regret Intensity Scale), occupational burnout prevalence (nonproprietary single-item measure), and risk preferences (uncertainty test and risk aversion assessment). The study findings will contribute to better understand relevant factors associated with therapeutic decisions of pediatric neurologists in spinal muscular atrophy, identifying treatment preferences and evaluating the role of behavioral aspects such as therapeutic inertia, herding, regret, and workplace burnout.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The study was funded by Roche Medical Department, Spain (SL42765). This does not alter our adherence to PLoS ONE policies on sharing data and materials. Gustavo Saposnik received unrestricted grants and personal fees from Hoffman La Roche (Canada) and Roche Farma (Spain), and reported being supported by the Heart and Stroke Foundation of Canada Scientist Award following an open peer-reviewed competition. Paola Díaz-Abós, Victoria Sánchez-Menéndez, Carmen Álvarez, Jorge Maurino, and María Brañas-Pampillón are employees of Roche Farma Spain. María Terzaghi and Ignacio Málaga declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0264006